Skip to main content

Table 4 Patient characteristics in the group younger than 80 years

From: Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age

 

Early use of TLV

Delayed use of TLV

P value

(n = 79)

(n = 67)

Body mass index (kg/m2)

21.7 ± 3.9

21.9 ± 4.2

0.778

NYHA class (II/III/IV)

1/68/10

0/54/13

0.203

CS class (I/II/III)

26/46/7

23/36/8

0.760

Systolic BP (mm Hg) on admission

131.7 ± 28.0

128.6 ± 31.7

0.533

Diastolic BP (mm Hg) on admission

69.7 ± 22.2

75.7 ± 17.9

0.073

Heart rate (bpm)

89.0 ± 23.5

94.7 ± 28.8

0.195

AST (IU/L)

62.4 ± 24.5

73.6 ± 24.9

0.750

ALT (IU/L)

51.6 ± 21.8

62.0 ± 25.2

0.754

eGFR (ml/min/1.73 m2)

49.0 ± 26.5

43.3 ± 21.5

0.156

Hemoglobin (g/dL)

12.6 ± 2.2

12.0 ± 3.2

0.229

Brain natriuretic peptide (pg/mL)

1153.2 ± 118.0

1529.3 ± 284.8

0.199

Ejection fraction (%)

45.3 ± 17.6

43.2 ± 19.5

0.509

HFpEF (n, %)

31, 39.2

25, 37.3

0.813

Length of hospital stay

21.0 ± 13.0

33.0 ± 22.7

< 0.001

Time until commencement of TLV from hospitalization

2.5 ± 1.0

12.7 ± 13.3

< 0.001

Length of hospital stay after initiation of TLV

18.6 ± 13.1

20.3 ± 16.9

0.479

  1. NYHA: New York Heart Association, CS: clinical scenario, BP: blood pressure, AST: aspartate aminotransferase, ALT: alanine aminotransferase, eGFR: estimated glomerular filtration rate, HFpEF: heart failure preserved ejection fraction, TLV: tolvaptan. Continuous data are expressed as the mean ± standard deviation or error. P-values were determined using the unpaired t-test